[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin].
Effect of an HMG-CoA reductase inhibitor pravastatin on atherogenic changes in the lipid transport system during postprandial hyperlipidemia immediately after ingestion of fatty meal was studied in patients with coronary heart disease and fasting hyperlipidemia. Treatment with pravastatin (20-40 mg/day for 3 months) resulted in normalization of fasting levels of blood lipids and decreased postprandial hyperlipidemia due to of enhanced removal of triglyceride-rich atherogenic lipoproteins from blood and their diminished secretion in response to fat load. Moreover pravastatin increased tolerance of the lipid-transport system to exogenous saturated fats. KEY WORDS. coronary heart disease; postprandial hyperlipidemia; pravastatin; lipoproteins, metabolism.
Bubnova
M G
MG
Aronov
D M
DM
Perova
N V
NV
Olfer'ev
A M
AM
Golubev
M A
MA
Mel'kina
O E
OE
Zhasminova
V G
VG
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D017035:Pravastatin / Q000627:therapeutic use*; D012720:Severity of Illness Index
D000924:Anticholesteremic Agents; D017035:Pravastatin